Most Read Articles
5 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 6 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 3 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Yesterday
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.

Atopic dermatitis ups mortality risk in adults

23 Feb 2018

Atopic dermatitis (AD) in adults is associated with an increased risk of death, a recent study has found. Furthermore, AD patients have a slightly elevated risk of death from cardiovascular, urogenital and infectious diseases, but the absolute risk is very low.

A total of 8,686 patients were matched with 86,860 controls in this study that investigated cause-specific death rates and risk in adults with AD.

Patients with AD had significantly elevated risk for death due to any cause (hazard ratio [HR], 1.27; 95 percent CI, 1.11–1.45). Significant causes included the following: cardiovascular (HR, 1.45; 1.07–1.96), infectious (HR, 3.71; 1.43–9.60) and urogenital diseases (HR, 5.51; 1.54–19.80).

In addition, there was no increased mortality risk due to cancer, endocrine, neurologic, psychiatric, respiratory or gastroenterologic disease.

The investigators performed cross-linkage of nationwide healthcare and cause of death registers. Adults with AD were matched 1:10 with controls. Cox proportional hazard models were used to calculate incidence rates per 1,000 person-years and HRs of cause-specific death.

“The results might not be generalizable to patients seen exclusively by primary care physicians,” according to the investigators.

Apart from mortality risk, AD may have significant impact on adults. A recent article has suggested that visible lesions “necessarily have consequences on all aspects of everyday life, including sleep, and professional, social, family and emotional life,” as well as financial consequences. Furthermore, AD can greatly affect quality of life and be a heavy burden to these adult patients. [Ann Dermatol Venereol 2017;144(suppl 5):VS23-VS28]

Editor's Recommendations
Most Read Articles
5 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 6 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 3 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Yesterday
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.